| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1370702 | Bioorganic & Medicinal Chemistry Letters | 2015 | 5 Pages |
Abstract
Current chemotherapy drugs for Chagas’ disease are insufficient due to their limited efficacy; however, anti-trypanosomal agents have recently shown promise. As such, synthetic intermediates of komaroviquinone were evaluated for anti-trypanosomal activity. Based on the results, a series of novel quinone derivatives were screened for anti-trypanosomal activity and mammalian cytotoxicity. Several quinone derivatives displayed higher antiprotozoal activity against Trypanosoma cruzi trypomastigotes than the reference drug benznidazole, without concomitant toxicity toward the host cell.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Yutaka Suto, Junko Nakajima-Shimada, Noriyuki Yamagiwa, Yoko Onizuka, Genji Iwasaki,